secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001437749-24-020335
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed completes enrollment in Phase 2b neflamapimod trial for DLB; topline data due Dec 2024
--------------------------------------------------------------------------------

- Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) fully enrolled.
- Topline data expected in December 2024 (16-week double-blind placebo-controlled period).
- Trial targets up to 160 patients; excludes AD co-pathology via plasma ptau181 screen (two-thirds eligible).
- Primary endpoint: Clinical Dementia Rating Sum of Boxes; funded by $21M NIH/NIA grant.
- 43 sites (32 US, 8 UK, 3 Netherlands) all initiated; open-label extension for 32 additional weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924020335/0001437749-24-020335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924020335/crvo20240613_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-020335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer